TherapeuticsMD Narrows Losses, Explores Sale After Royalty Pivot

BOCA RATON, Fla. – March 30, 2026

TherapeuticsMD, Inc. (NASDAQ: TXMD) today signaled a pivotal moment in its corporate journey, reporting a significant financial turnaround for the full year 2025 and simultaneously confirming it is actively exploring strategic alternatives, including a potential merger or sale. The announcement comes just over three years after the company abandoned its role as a commercial operator in women's health to become a leaner, royalty-focused entity.

The annual report paints a picture of a company stabilizing after a dramatic transformation. The strategic pivot appears to be bearing fruit, with narrowed losses and surging revenue streams breathing new life into its financial statements. However, the concurrent search for a strategic transaction suggests that this stabilization may be a prelude to a new chapter, potentially under different ownership.

A Turnaround Story in the Numbers

The financial results for the year ended December 31, 2025, highlight the profound impact of the company's streamlined business model. TherapeuticsMD reported a net loss from continuing operations of just $(0.7) million, or $(0.06) per share. This represents a substantial improvement from the $(2.3) million net loss in 2024 and an even more dramatic recovery from a $(7.7) million loss in 2023. This steady reduction in losses underscores the cost-efficiency of the royalty model, which has shed the heavy operational and R&D expenses of its past.

Fueling this turnaround is a robust increase in license revenue, which totaled $3.0 million for 2025. This marks a 71.6% increase compared to the $1.8 million generated in 2024. The revenue growth demonstrates a positive trend since the company's transition, building on the $1.3 million in license revenue from 2023. According to the company, this growth is “primarily attributable to changes in sales of licensed products.”

Complementing the revenue growth, total operating expenses continued their downward trend, falling 5.9% to $7.4 million in 2025 from $7.9 million in 2024. The company attributed this decrease mainly to lower impairment charges, although this was partially offset by higher bonus expenses and costs related to investor communications. The company's balance sheet also reflects newfound stability, with cash and cash equivalents growing to $7.5 million as of year-end 2025, up from $5.1 million the previous year.

The Mayne Pharma Engine

Central to TherapeuticsMD's current existence is its comprehensive licensing agreement with Mayne Pharma Group, finalized in early 2023. This deal effectively outsourced the commercial fate of its core products, allowing TherapeuticsMD to recapitalize and step back from direct market engagement. Mayne Pharma gained exclusive U.S. rights to commercialize the menopause hormone therapies Imvexxy® and Bijuva®, the contraceptive ring Annovera®, and a portfolio of prescription prenatal vitamins.

The financial terms of the deal provided an immediate lifeline, with an upfront payment of $140 million and an additional $13.1 million for working capital. More importantly for its long-term viability, the agreement established a steady royalty stream. TherapeuticsMD is entitled to receive 8% on the first $80 million in annual net sales and 7.5% thereafter, with a guaranteed minimum of $3 million per year for 12 years. The impressive 71.6% growth in license revenue in 2025 suggests that Mayne Pharma's commercialization efforts are gaining traction, driving sales beyond the minimum thresholds and validating the strategic partnership.

Beyond Royalties: What’s Next?

With its finances on a more solid footing, TherapeuticsMD has formally announced its exploration of “a variety of strategic alternatives.” The language is broad, encompassing possibilities that “may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions.”

This move is a logical next step for a company that has successfully transitioned into a pure-play asset holder. In the current biopharma M&A landscape, there is a strong appetite for de-risked, revenue-generating assets. TherapeuticsMD, with its patent-protected products and predictable royalty income, fits this profile. By streamlining its operations and proving the value of its royalty stream, the company has effectively packaged itself as an attractive target for larger pharmaceutical companies or specialized royalty acquisition funds.

While the company has set no timetable for this process and does not intend to provide updates unless a deal is reached, the announcement itself puts TherapeuticsMD officially in play. For shareholders, this phase introduces both opportunity and uncertainty. A potential acquisition could unlock significant value, but the final outcome remains unknown. The market has responded with cautious optimism; while the company's stock has seen a remarkable 125% increase over the past year, it saw a slight dip following the earnings release, reflecting the inherent uncertainty of a strategic review.

The Realities of a Royalty Model

TherapeuticsMD now serves as a compelling case study on the viability of the pure-play pharmaceutical royalty model. The benefits are clear: low overhead, predictable revenue, and insulation from the costly risks of drug development and marketing. However, the model is not without its own set of challenges.

The company’s fate is inextricably linked to the performance of its licensee, Mayne Pharma. Any struggles in marketing, manufacturing, or navigating market access for the licensed products directly impact TherapeuticsMD’s top line. This dependency is highlighted in the company's own risk factors, which cite its reliance on third parties and the potential for disputes. The forward-looking statements mention “ongoing disputes with Mayne Pharma,” a stark reminder that even well-structured partnerships can face friction.

Furthermore, the 'going concern' language that persists in the company's SEC filings, while standard for many companies in transition, points to underlying risks that must be managed. The strategic review can be seen as a proactive measure to address these long-term concerns by finding a permanent home for its assets that can maximize their value. As the board evaluates its options, the central question will be whether the company’s future is best served by continuing as a standalone royalty entity or by integrating its valuable assets into a larger organization.